NCT01511185View on ClinicalTrials.gov

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

A single dose of 7.5 mcg/kg administered subcutaneously in random order

DRUG

placebo

A single dose administered subcutaneously in random order

Trial Locations (1)

48109-0926

Novo Nordisk Investigational Site, Ann Arbor

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY